Difference between revisions of "Nilutamide (Nilandron)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://products.sanofi.us/nilandron/nilandron.pdf Nilutamide (Nilandron) package insert]</ref><ref>[http://hemonc.org...") |
m |
||
| (14 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://products.sanofi.us/nilandron/nilandron.pdf Nilutamide (Nilandron) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/nilutamide.pdf Nilutamide (Nilandron) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Antiandrogen, nonsteroidal. Nilutamide competitively inhibits the effects of testosterone by interacting with the androgen receptor.<ref name="insert">[http://products.sanofi.us/nilandron/nilandron.pdf Nilutamide (Nilandron) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/nilutamide.pdf Nilutamide (Nilandron) package insert (locally hosted backup)]</ref> |
| − | <br>Route: | + | <br>Route: PO |
| − | <br>Extravasation: | + | <br>Extravasation: n/a |
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Prostate cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://chemocare.com/bio/nilutamide.asp Nilutamide (Nilandron) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/nilutamide.asp Nilutamide (Nilandron) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/nilutamide.asp Nilutamide (Nilandron) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/nilutamide.asp Nilutamide (Nilandron) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/nilutamide-patient-drug-information Nilutamide (Nilandron) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/nilutamide-patient-drug-information Nilutamide (Nilandron) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/nilutamide-patient-drug-information Nilutamide (Nilandron) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/nilutamide-patient-drug-information Nilutamide (Nilandron) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *1996-09-19: Initial approval in combination with surgical castration for the treatment of stage D2 metastatic [[prostate cancer|carcinoma of the prostate]]. ''(Based on International Anandron Study)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | *1986-07-02: EURD | ||
| + | ==Also known as== | ||
| + | *'''Brand names:''' Anandron, Nilandron, Zandron | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Oral medications]] | ||
| + | |||
| + | [[Category:First-generation nonsteroidal antiandrogens]] | ||
| + | |||
| + | [[Category:Prostate cancer medications]] | ||
| + | |||
| + | [[Category:FDA approved in 1996]] | ||
| + | [[Category:EMA approved in 1986]] | ||
Revision as of 02:01, 14 June 2023
General information
Class/mechanism: Antiandrogen, nonsteroidal. Nilutamide competitively inhibits the effects of testosterone by interacting with the androgen receptor.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Nilutamide (Nilandron) patient drug information (Chemocare)[3]
- Nilutamide (Nilandron) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1996-09-19: Initial approval in combination with surgical castration for the treatment of stage D2 metastatic carcinoma of the prostate. (Based on International Anandron Study)
History of changes in EMA indication
- 1986-07-02: EURD
Also known as
- Brand names: Anandron, Nilandron, Zandron